Compare DCTH & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | ORGO |
|---|---|---|
| Founded | 1988 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.5M | 299.8M |
| IPO Year | 2015 | 2016 |
| Metric | DCTH | ORGO |
|---|---|---|
| Price | $13.55 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $22.00 | $8.50 |
| AVG Volume (30 Days) | 573.8K | ★ 704.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 107.53 | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | $24.54 | N/A |
| Revenue Next Year | $33.15 | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $8.12 | $2.04 |
| 52 Week High | $13.44 | $7.08 |
| Indicator | DCTH | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 70.39 | 50.56 |
| Support Level | $10.26 | $2.26 |
| Resistance Level | N/A | $2.58 |
| Average True Range (ATR) | 0.57 | 0.11 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 92.89 | 57.08 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.